REPL
Replimune Group, Inc.$9.78-0.07 (-0.71%)Prev Close$9.87·MCap$966.2M·P/E—·Vol1.17M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
13
$943.9K
◆
Net Activity
Net Seller
$943.9K
●
Active Insiders
7
last 12 mo
Over the past 12 months, insider activity at Replimune Group, Inc. (REPL) has been exclusively selling, with 0 insider purchases totaling $0.00 and 13 insider sales totaling $943.9K. The most recent insider transaction was by Sarchi Christopher (officer: Chief Commercial Officer), who sold $110.9K worth of shares on Jun 3, 2026. Replimune Group, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $966.2M.
REPL Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | Sarchi Christopher | officer: Chief Commercial Officer | Sell | 12,000 | $9.24 | $110.9K | 180,962 |
| May 20, 2026 | Patel Sushil | director, officer: Chief Executive Officer | Sell | 37,324 | $5.08 | $189.6K | 747,492 |
| May 20, 2026 | Astley-Sparke Philip | director | Sell | 17,657 | $5.08 | $89.7K | 1,412,414 |
| May 20, 2026 | Sarchi Christopher | officer: Chief Commercial Officer | Sell | 8,626 | $5.08 | $43.8K | 192,962 |
| May 20, 2026 | Schwendenman Andrew | officer: Chief Accounting Officer | Sell | 7,894 | $5.08 | $40.1K | 107,057 |
| May 20, 2026 | Xynos Konstantinos | officer: Chief Medical Officer | Sell | 14,023 | $5.08 | $71.2K | 235,662 |
| May 20, 2026 | Hill Emily Luisa | officer: Chief Financial Officer | Sell | 7,812 | $5.08 | $39.7K | 236,556 |
| Apr 6, 2026 | Sarchi Christopher | officer: Chief Commercial Officer | Sell | 6,500 | $8.01 | $52.1K | 151,588 |
| Dec 11, 2025 | Dhingra Kapil | Director | Sell | 3,169 | $10.40 | $33.0K | 0Exit |
| Dec 4, 2025 | Patel Sushil | Chief Executive Officer | Sell | 10,000 | $11.13 | $111.3K | 333,576 |
| Nov 19, 2025 | Sarchi Christopher | Chief Commercial Officer | Sell | 5,208 | $9.10 | $47.4K | 123,088 |
| Nov 19, 2025 | Xynos Konstantinos | Chief Medical Officer | Sell | 7,248 | $9.10 | $66.0K | 139,685 |
| Aug 19, 2025 | Hill Emily Luisa | Chief Financial Officer | Sell | 9,154 | $5.37 | $49.2K | 134,368 |
| May 22, 2025 | Astley-Sparke Philip | Director | Sell | 32,279 | $8.06 | $260.2K | 1,405,071 |
| May 22, 2025 | Hill Emily Luisa | Chief Financial Officer | Sell | 2,535 | $8.05 | $20.4K | 143,522 |
| May 22, 2025 | Patel Sushil | Chief Executive Officer | Sell | 25,105 | $8.06 | $202.3K | 343,576 |
| May 22, 2025 | Sarchi Christopher | Chief Commercial Officer | Sell | 3,749 | $8.05 | $30.2K | 128,296 |
| May 22, 2025 | Schwendenman Andrew | Chief Accounting Officer | Sell | 3,287 | $8.05 | $26.5K | 68,284 |
| May 22, 2025 | Xynos Konstantinos | Chief Medical Officer | Sell | 7,952 | $8.06 | $64.1K | 146,933 |
| Dec 18, 2024 | Patel Sushil | Chief Executive Officer | Sell | 10,000 | $12.42 | $124.2K | 202,014 |
| Nov 20, 2024 | Sarchi Christopher | Chief Commercial Officer | Sell | 5,207 | $10.78 | $56.1K | 87,045 |
| Nov 20, 2024 | Xynos Konstantinos | Chief Medical Officer | Sell | 7,246 | $10.78 | $78.1K | 109,885 |
| Aug 19, 2024 | Hill Emily Luisa | Chief Financial Officer | Sell | 8,938 | $10.18 | $91.0K | 101,057 |
| Jun 10, 2024 | Xynos Konstantinos | Chief Medical Officer | Sell | 15,881 | $7.50 | $119.1K | 117,131 |
| May 20, 2024 | Astley-Sparke Philip | Executive Chairman | Sell | 37,928 | $6.47 | $245.4K | 1,487,350 |
| May 20, 2024 | Coffin Robert | Director | Sell | 11,464 | $6.47 | $74.2K | 1,821,872 |
| May 20, 2024 | Love Colin | Chief Operating Officer | Sell | 17,615 | $6.47 | $114.0K | 777,345 |
| May 20, 2024 | Patel Sushil | Chief Executive Officer | Sell | 20,194 | $6.47 | $130.7K | 212,014 |
| May 20, 2024 | Sarchi Christopher | Chief Commercial Officer | Sell | 2,218 | $6.47 | $14.4K | 92,252 |
| May 20, 2024 | Schwendenman Andrew | Chief Accounting Officer | Sell | 2,298 | $6.47 | $14.9K | 38,238 |
| May 20, 2024 | Xynos Konstantinos | Chief Medical Officer | Sell | 6,367 | $6.47 | $41.2K | 133,012 |
| Nov 17, 2023 | Sarchi Christopher | Chief Commercial Officer | Sell | 5,255 | $10.92 | $57.4K | 72,245 |
| Nov 17, 2023 | Xynos Konstantinos | Chief Medical Officer | Sell | 7,313 | $10.92 | $79.9K | 112,714 |
| Sep 13, 2023 | Esposito Pamela | Chief Business Officer | Sell | 5,658 | $20.01 | $113.2K | 263,436 |
| Aug 24, 2023 | Esposito Pamela | Chief Business Officer | Sell | 18,600 | $20.01 | $372.2K | 263,436 |
| Aug 15, 2023 | Esposito Pamela | Chief Business Officer | Sell | 1,400 | $20.00 | $28.0K | 263,436 |
| Jul 11, 2023 | Esposito Pamela | Chief Business Officer | Sell | 20,000 | $21.58 | $431.5K | 265,513 |
| Jun 15, 2023 | Lewis Tanya | Chief Dev. Op. Officer | Sell | 12,860 | $24.06 | $309.4K | 136,110 |
| Jun 15, 2023 | Patel Sushil | Chief Strategy Officer | Sell | 5,698 | $24.04 | $137.0K | 149,426 |
| May 18, 2023 | Astley-Sparke Philip | Chief Executive Officer | Sell | 17,902 | $18.05 | $323.1K | 1,525,278 |
| May 18, 2023 | Coffin Robert | President & Chief R&D Officer | Sell | 7,861 | $18.05 | $141.9K | 1,833,336 |
| May 18, 2023 | Esposito Pamela | Chief Business Officer | Sell | 5,966 | $18.05 | $107.7K | 263,436 |
| May 18, 2023 | Franchi Jean M. | Chief Financial Officer | Sell | 11,351 | $18.05 | $204.9K | 128,748 |
| May 18, 2023 | Lewis Tanya | Chief Dev. Op. Officer | Sell | 12,207 | $18.05 | $220.3K | 148,153 |
| May 18, 2023 | Love Colin | Chief Operating Officer | Sell | 10,775 | $18.05 | $194.5K | 794,960 |
| May 18, 2023 | Patel Sushil | Chief Strategy Officer | Sell | 15,575 | $18.05 | $281.1K | 154,571 |
| May 18, 2023 | Xynos Konstantinos | Chief Medical Officer | Sell | 771 | $18.05 | $13.9K | 120,027 |
| Dec 13, 2022 | Esposito Pamela | Chief Business Officer | Sell | 15,000 | $25.03 | $375.4K | 229,402 |
| May 18, 2022 | Astley-Sparke Philip | Chief Executive Officer | Sell | 9,632 | $14.59 | $140.5K | 1,401,080 |
| May 18, 2022 | Coffin Robert | President & Chief R&D Officer | Sell | 5,737 | $14.59 | $83.7K | 1,796,197 |
Showing 1–50 of 76
1 / 2
REPL Insider Buying Activity
The following table shows recent insider purchases of Replimune Group, Inc. (REPL) stock reported via SEC Form 4 filings.
No insider buying activity found for REPL in the last 12 months.
REPL Insider Selling Activity
The following table shows recent insider sales of Replimune Group, Inc. (REPL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | Sarchi Christopher | officer: Chief Commercial Officer | Sell | 12,000 | $9.24 | $110.9K | 180,962 |
| May 20, 2026 | Patel Sushil | director, officer: Chief Executive Officer | Sell | 37,324 | $5.08 | $189.6K | 747,492 |
| May 20, 2026 | Astley-Sparke Philip | director | Sell | 17,657 | $5.08 | $89.7K | 1,412,414 |
| May 20, 2026 | Sarchi Christopher | officer: Chief Commercial Officer | Sell | 8,626 | $5.08 | $43.8K | 192,962 |
| May 20, 2026 | Schwendenman Andrew | officer: Chief Accounting Officer | Sell | 7,894 | $5.08 | $40.1K | 107,057 |
| May 20, 2026 | Xynos Konstantinos | officer: Chief Medical Officer | Sell | 14,023 | $5.08 | $71.2K | 235,662 |
| May 20, 2026 | Hill Emily Luisa | officer: Chief Financial Officer | Sell | 7,812 | $5.08 | $39.7K | 236,556 |
| Apr 6, 2026 | Sarchi Christopher | officer: Chief Commercial Officer | Sell | 6,500 | $8.01 | $52.1K | 151,588 |
| Dec 11, 2025 | Dhingra Kapil | Director | Sell | 3,169 | $10.40 | $33.0K | 0Exit |
| Dec 4, 2025 | Patel Sushil | Chief Executive Officer | Sell | 10,000 | $11.13 | $111.3K | 333,576 |
| Nov 19, 2025 | Sarchi Christopher | Chief Commercial Officer | Sell | 5,208 | $9.10 | $47.4K | 123,088 |
| Nov 19, 2025 | Xynos Konstantinos | Chief Medical Officer | Sell | 7,248 | $9.10 | $66.0K | 139,685 |
| Aug 19, 2025 | Hill Emily Luisa | Chief Financial Officer | Sell | 9,154 | $5.37 | $49.2K | 134,368 |
| May 22, 2025 | Astley-Sparke Philip | Director | Sell | 32,279 | $8.06 | $260.2K | 1,405,071 |
| May 22, 2025 | Hill Emily Luisa | Chief Financial Officer | Sell | 2,535 | $8.05 | $20.4K | 143,522 |
| May 22, 2025 | Patel Sushil | Chief Executive Officer | Sell | 25,105 | $8.06 | $202.3K | 343,576 |
| May 22, 2025 | Sarchi Christopher | Chief Commercial Officer | Sell | 3,749 | $8.05 | $30.2K | 128,296 |
| May 22, 2025 | Schwendenman Andrew | Chief Accounting Officer | Sell | 3,287 | $8.05 | $26.5K | 68,284 |
| May 22, 2025 | Xynos Konstantinos | Chief Medical Officer | Sell | 7,952 | $8.06 | $64.1K | 146,933 |
| Dec 18, 2024 | Patel Sushil | Chief Executive Officer | Sell | 10,000 | $12.42 | $124.2K | 202,014 |
| Nov 20, 2024 | Sarchi Christopher | Chief Commercial Officer | Sell | 5,207 | $10.78 | $56.1K | 87,045 |
| Nov 20, 2024 | Xynos Konstantinos | Chief Medical Officer | Sell | 7,246 | $10.78 | $78.1K | 109,885 |
| Aug 19, 2024 | Hill Emily Luisa | Chief Financial Officer | Sell | 8,938 | $10.18 | $91.0K | 101,057 |
| Jun 10, 2024 | Xynos Konstantinos | Chief Medical Officer | Sell | 15,881 | $7.50 | $119.1K | 117,131 |
| May 20, 2024 | Astley-Sparke Philip | Executive Chairman | Sell | 37,928 | $6.47 | $245.4K | 1,487,350 |
| May 20, 2024 | Coffin Robert | Director | Sell | 11,464 | $6.47 | $74.2K | 1,821,872 |
| May 20, 2024 | Love Colin | Chief Operating Officer | Sell | 17,615 | $6.47 | $114.0K | 777,345 |
| May 20, 2024 | Patel Sushil | Chief Executive Officer | Sell | 20,194 | $6.47 | $130.7K | 212,014 |
| May 20, 2024 | Sarchi Christopher | Chief Commercial Officer | Sell | 2,218 | $6.47 | $14.4K | 92,252 |
| May 20, 2024 | Schwendenman Andrew | Chief Accounting Officer | Sell | 2,298 | $6.47 | $14.9K | 38,238 |
| May 20, 2024 | Xynos Konstantinos | Chief Medical Officer | Sell | 6,367 | $6.47 | $41.2K | 133,012 |
| Nov 17, 2023 | Sarchi Christopher | Chief Commercial Officer | Sell | 5,255 | $10.92 | $57.4K | 72,245 |
| Nov 17, 2023 | Xynos Konstantinos | Chief Medical Officer | Sell | 7,313 | $10.92 | $79.9K | 112,714 |
| Sep 13, 2023 | Esposito Pamela | Chief Business Officer | Sell | 5,658 | $20.01 | $113.2K | 263,436 |
| Aug 24, 2023 | Esposito Pamela | Chief Business Officer | Sell | 18,600 | $20.01 | $372.2K | 263,436 |
| Aug 15, 2023 | Esposito Pamela | Chief Business Officer | Sell | 1,400 | $20.00 | $28.0K | 263,436 |
| Jul 11, 2023 | Esposito Pamela | Chief Business Officer | Sell | 20,000 | $21.58 | $431.5K | 265,513 |
| Jun 15, 2023 | Lewis Tanya | Chief Dev. Op. Officer | Sell | 12,860 | $24.06 | $309.4K | 136,110 |
| Jun 15, 2023 | Patel Sushil | Chief Strategy Officer | Sell | 5,698 | $24.04 | $137.0K | 149,426 |
| May 18, 2023 | Astley-Sparke Philip | Chief Executive Officer | Sell | 17,902 | $18.05 | $323.1K | 1,525,278 |
| May 18, 2023 | Coffin Robert | President & Chief R&D Officer | Sell | 7,861 | $18.05 | $141.9K | 1,833,336 |
| May 18, 2023 | Esposito Pamela | Chief Business Officer | Sell | 5,966 | $18.05 | $107.7K | 263,436 |
| May 18, 2023 | Franchi Jean M. | Chief Financial Officer | Sell | 11,351 | $18.05 | $204.9K | 128,748 |
| May 18, 2023 | Lewis Tanya | Chief Dev. Op. Officer | Sell | 12,207 | $18.05 | $220.3K | 148,153 |
| May 18, 2023 | Love Colin | Chief Operating Officer | Sell | 10,775 | $18.05 | $194.5K | 794,960 |
| May 18, 2023 | Patel Sushil | Chief Strategy Officer | Sell | 15,575 | $18.05 | $281.1K | 154,571 |
| May 18, 2023 | Xynos Konstantinos | Chief Medical Officer | Sell | 771 | $18.05 | $13.9K | 120,027 |
| Dec 13, 2022 | Esposito Pamela | Chief Business Officer | Sell | 15,000 | $25.03 | $375.4K | 229,402 |
| May 18, 2022 | Astley-Sparke Philip | Chief Executive Officer | Sell | 9,632 | $14.59 | $140.5K | 1,401,080 |
| May 18, 2022 | Coffin Robert | President & Chief R&D Officer | Sell | 5,737 | $14.59 | $83.7K | 1,796,197 |
REPL Insiders
Similar Stocks to REPL
VRTX
Vertex Pharmaceuticals Incorporated
$476.29+0.08%
$126.50B
REGN
Regeneron Pharmaceuticals, Inc.
$662.73+1.01%
$68.29B
ALNY
Alnylam Pharmaceuticals, Inc.
$275.93-1.72%
$43.19B
RVMD
Revolution Medicines, Inc.
$185.71+0.42%
$40.34B
MRNA
Moderna, Inc.
$68.11+1.00%
$27.09B
INSM
Insmed Incorporated
$109.25-0.67%
$25.06B
INCY
Incyte Corporation
$114.43-0.30%
$23.32B
UTHR
United Therapeutics Corporation
$530.63+0.75%
$23.22B